Long-term adjuvant ADT improves results of brachy-boost therapy in unfavorable-risk prostate cancer patients

TROG 01.03 RADAR, begun in 2003, was a (partly) randomized clinical trial to help optimize therapy of unfavorable-risk patients. … READ MORE …

Radiation therapy for prostate cancer in the time of COVID-19

A panel of top radiation oncologists in the US and the UK has addressed the question of putting off or shortening various kinds of radiation treatment (RT) for prostate cancer at a time when it is best to maintain distance from institutions that treat patients. … READ MORE …

“Adjuvant” similar to “early salvage” radiation outcome in meta-analysis

Although at least three randomized clinical trials have told us that adjuvant radiation after prostatectomy often affords better results than just taking a “wait-and-see” approach, … READ MORE …

The first-line treatment of locally advanced prostate cancer (clinical stage T3)

Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy (ADT) among patients initially diagnosed with locally advanced (T3) prostate cancer? … READ MORE …

SABR to oligometastases slows progression via immune response

Stereotactic ablative body radiation (SABR, or sometimes, SBRT) significantly slowed metastatic progression in men with three or fewer metastases (oligometastatic disease). … READ MORE …

Adjuvant chemotherapy does NOT improve BDFS rates in men with intermediate- and high-risk prostate cancer

With the third Advanced Prostate Cancer Consensus Conference (APCCC) due to start here in Basel, Switzerland, this morning, there is an important new set of data that will help to inform some of the discussions. … READ MORE …

Evidence for dose escalation in adjuvant/salvage radiation

It is well known that prostate cancer is relatively radio-resistant compared to other kinds of cancer. … READ MORE …